Regeneron's Inmazeb Overcame FDA Combo Product Requirements With Nonclinical Evidence

 
• By Sue Sutter
  
Three gears
Using a combination of three mABs is likely to reduce the chance that Inmazeb's efficacy will be impacted by resistance. • Source: Shutterstock

More from Drug Review Profiles

More from Product Reviews